FDA-Approved Drug Library Plus | FDA 上市库 Plus | MedChemExpress (MCE)

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,282 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library Plus, with more powerful screening capability, further complements FDA-Approved Drug Library (HY-L022) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.更多产品详情查看：www.medchemexpress.cn/screening/fda-approved-drug-library-plus.html

FDA-Approved Drug Library Plus | FDA 上市库 Plus | MedChemExpress (MCE)信息由MedChemExpress (MCE)为您提供，如您想了解更多关于FDA-Approved Drug Library Plus | FDA 上市库 Plus | MedChemExpress (MCE)报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途